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Introduction
Rhinosinusitis (RS) is an inﬂammatory process of the nasal
mucosa, and it is classiﬁed as acute (<12 weeks) or chronic
(≥12 weeks) according to the time required for the evolution
of signs and symptoms, and according to the severity of the
condition, as Mild, Moderate or Severe. Disease severity is
classiﬁed through the Visual Analog Scale (VAS) (Fig. 1), from
0 to 10 cm. The patient is asked to quantify from 0 to 10 the
degree of discomfort caused by the symptoms; zero meaning
no discomfort, and 10, the greatest discomfort. Severity is
then classiﬁed as follows: Mild: 0--3 cm; moderate: >3--7 cm;
Severe: >7--10 cm.1
Although VAS has only been validated for Chronic Rhi-
nosinusitis (CRS) in adults, the European Position Paper on
Rhinosinusitis and Nasal Polyps (EPOS) 20121 also recom-
mends its use for Acute Rhinosinusitis (ARS). There are
several speciﬁc questionnaires for rhinosinusitis; however,
in practice, most have limited application, particularly in
acute conditions.2--4
Acute rhinosinusitis
Deﬁnition
Acute rhinosinusitis (ARS) is an inﬂammatory process of the
nasal mucosa of sudden onset, lasting up to 12 weeks. It can
occur one or more times within a given period, but always
with complete remission of signs and symptoms between
episodes.
Classiﬁcation
There are several classiﬁcations for rhinosinusitis. One of
the most often used is the etiological classiﬁcation, which
is based primarily on symptom duration:1
- Viral or common cold ARS: a generally self-limited condi-
tion, in which symptom duration is less than ten days;
- Post-viral ARS: when there is worsening of symptoms ﬁve
days after the onset of disease, or when symptoms persist
for more than ten days;
- Acute bacterial rhinosinusitis (ABRS): small percentage of
patients with post-viral ARS can develop ABRS.
The viral ARS or common cold has a symptom duration
that is traditionally less than 10 days. When there is symp-
tom worsening around the ﬁfth day, or persistence beyond
ten days (and less than 12 weeks), it could be classiﬁed as
a post-viral RS. It is estimated that a small percentage of
post-viral ARS develops into ABRS, around 0.5--2%.
Regardless of time of duration, the presence of at least
three of the signs/symptoms below may suggest bacterial
ARS:
- Nasal secretion (with unilateral predominance) and pres-
ence of pus in the nasal cavity;
Figure 1 Visual Analog Scale (VAS).
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Intense local pain (with unilateral predominance);
Fever >38 ◦C;
Elevated erythrocyte sedimentation rate (ESR) and C-
reactive protein (CRP) levels;
‘‘Double worsening’’: acute relapse or deterioration after
the initial period of mild symptoms.
linical diagnosis
igns and symptoms
t the level of primary health care and for epidemiological
urposes, ARS can be diagnosed based on symptoms alone,
ithout detailed otorhinolaryngological examination and/or
maging studies. In these cases, the distinction between
ypes of ARS is mainly by means of medical history and
hysical examination performed by medical generalists and
pecialists, either otorhinolaryngologists or not. It is worth
entioning that, at the time of the medical assessment,
atients may fail to report ‘‘worsening’’ if not asked specif-
cally. The history of a duration of symptoms lasting a few
ays followed by a relapse is frequent. It is up to the assis-
ant physician to recognize that, and in most cases, it could
epresent the evolution of the same disease, from a viral
RS to a post-viral one, rather than two distinct infections.
ubjective evaluation of patients with ARS and its diagnosis
re based on the presence of two or more of the following
ardinal symptoms:1
Nasal obstruction/congestion;
Anterior or posterior nasal discharge/rhinorrhea (most
often, but not always, purulent);
Facial pain/pressure/headache;
Olfactory disorder.
In addition to the above symptoms, odynophagia, dyspho-
ia, cough, ear fullness and pressure and systemic symptoms
uch as asthenia, malaise and fever may also occur. The few
tudies on the frequency of these symptoms in ARS in the
ommunity have shown great variability.5--7 The possibility
f ABRS is greater in the presence of three or more of the
ollowing signs and symptoms:1
Nasal secretion/presence of pus in the nasal cavity with
unilateral predominance;
Local pain with unilateral predominance;
Fever >38 ◦C;
Symptom worsening/deterioration after the initial dis-
ease period;
Elevated erythrocyte sedimentation rate (ESR) and C-
reactive protein (CRP) levels.
ARS symptoms have a characteristically sudden onset,
ithout a recent history of rhinosinusitis symptoms. In the
cute exacerbation of chronic rhinosinusitis (CRS), diagnos-
ic criteria and treatments similar to those used for ARS
hould be used.1 Cough, although considered an important
ymptom according to most international guidelines, is not
ne of the cardinal symptoms in this document. In the pedi-
tric population, however, cough is identiﬁed as one of the
our cardinal symptoms, rather than olfactory disorders.1,8
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Nasal obstruction is one of the important symptoms of
RS and should be evaluated together with other patient
omplaints. Although methods of objective evaluation of
asal obstruction such as rhinomanometry, nasal peak inspi-
atory ﬂow and acoustic rhinometry are rarely applied in
aily practice in patients with ARS, studies have shown good
orrelation between the symptoms reported by patients and
bjective measurements obtained by these methods.1
Purulent rhinorrhea is often interpreted in clinical
ractice as an indicator of bacterial infection requiring the
se of antibiotics.9,10 However, the evidence for this asso-
iation is limited. Despite being a symptom that seems to
ncrease the chances of positive bacterial culture, purulent
hinorrhea alone does not characterize ABRS.11 Purulent rhi-
orrhea with unilateral predominance and the presence of
us in the nasal cavity have a positive predictive value of
nly 50% and 17%, respectively, for positive bacterial culture
btained by maxillary sinus aspirate.12 Therefore, the pres-
nce of purulent rhinorrhea does not necessarily indicate the
xistence of bacterial infection and should not be consid-
red as an isolated criterion for antibiotic prescription.11--13
Reduction in the sense of smell is one of the most
ifﬁcult symptoms to quantify in clinical practice and is
sually evaluated only subjectively. Hyposmia and anosmia
re complaints commonly associated with ARS, which can
e assessed by validated objective tests and with subjec-
ive scales that exhibit good correlation.14,15 It is important
hat these olfactory function tests go through the process
f translation, cultural and socioeconomic adaptation to be
sed in different populations.16
Facial pain and pressure commonly occur in ARS. When
nilateral, facial or even dental pain has been considered
predictor of acute maxillary sinusitis.5,17 The complaint
f dental pain in the upper teeth on the topography of
he maxillary sinus showed a statistically signiﬁcant asso-
iation with the presence of positive bacterial culture,
ith a predominance of Streptococcus pneumoniae and
aemophilus inﬂuenzae, obtained by sinus aspirate.18 How-
ver, in another study, the positive predictive value of the
nilateral face pain symptom for bacterial infection was only
1%.17
Several studies and guidelines have sought to deﬁne the
ombination of symptoms that best determine the higher
robability of bacterial infection and antibiotic response.1
n the study by Berg and Carenfelt,7 the presence of two
r more ﬁndings (purulent rhinorrhea and local pain with
nilateral predominance, pus in the nasal cavity and bilat-
ral purulent rhinorrhea) showed 95% sensitivity and 77%
peciﬁcity for the diagnosis of ABRS.
Clinical examination of the patient with ARS should
nvolve, initially, the measurement of vital signs and physi-
al examination of the head and neck, with special attention
o the presence of localized or diffuse facial edema. At
he oroscopy, posterior purulent secretion in the orophar-
nx is an important ﬁnding.8 Anterior rhinoscopy is a part of
he physical examination that should be performed in the
rimary evaluation of patients with nasal symptoms, and
lthough it offers limited information, it may disclose impor-
ant aspects of the nasal mucosa and secretions.1 Fever
ay be present in some patients with ARS in the ﬁrst days
f infection,19 and when higher than 38 ◦C it is considered
ndicative of more severe disease and may indicate the
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eed for more aggressive treatment, especially when associ-
ted with other severe symptoms. Fever is also signiﬁcantly
ssociated with positive bacterial culture obtained by nasal
spirate especially S. pneumoniae and H. inﬂuenzae.
Despite the limited data in the literature, in patients
ith ARS, the presence of edema and pain on palpation of
he maxillofacial region may be indicative of more severe
isease, requiring antibiotics.9
At the primary health care levels, nasal endoscopy is
enerally not routinely available and is not considered a
ompulsory examination for the diagnosis of ARS. When
vailable, it allows the specialist better visualization of
he nasal anatomy and topographic diagnosis, as well as an
pportunity to obtain material for microbiological analysis.1
t the assessment and clinical examination of patients,
ossible variations between geographical regions and dif-
erent populations should be considered. Climatic, social,
conomic and cultural differences, as well as diverse oppor-
unity of health care access, among other factors, may
hange the subjective perception of the disease, as well as
otentially generate peculiar clinical features. The impor-
ance of this variability is unknown from the point of view
f scientiﬁc evidence; more studies are necessary to detect
hem.
reatment
here is worldwide concern with the indiscriminate use of
ntibiotics and with the development of bacterial resistance
xists worldwide. It is estimated that approximately 50 mil-
ion antibiotic prescriptions for rhinosinusitis in the USA are
nnecessary, being prescribed for viral infections. When the
atient follows a more selective algorithm for antibiotic
reatment, the beneﬁt is greater, and it is only necessary to
reat three patients for one to reach the expected result.20
hus, there is a worldwide trend to treat ARS according to
isease severity and duration.
ntibiotics
eta-analyses with placebo-controlled, randomized,
ouble-blind clinical trials show the efﬁcacy of antibiotics
n improving symptoms of patients with ABRS, especially if
dministered carefully. They are not indicated in cases of
iral rhinosinusitis, as they do not alter the disease course,21
nd should never be prescribed as symptomatic treatment,
hus avoiding indiscriminate use that may contribute to
ncreased bacterial resistance.22
Clinical studies have demonstrated that approximately
5% of the patients diagnosed with ABRS have spontaneous
linical resolution,23 and in some cases mild ABRS can resolve
pontaneously within the ﬁrst ten days;21 therefore, the
nitial adjuvant treatment, without antibiotics, may be a
iable option for mild and/or post-viral RS. The introduc-
ion of antibiotics should be considered when there is no
mprovement after treatment with adjuvant measures or
f the symptoms are increasing in severity. Antibiotics are
ndicated in cases of moderate to severe ABRS, in patients
ith severe symptoms (fever >37.8 ◦C and severe facial pain)
nd in immunocompromised patients, regardless of the dis-
ase duration, and in cases of mild or uncomplicated ABRS
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that do not improve with initial treatment with topical nasal
corticosteroids.24,25
There are no studies to deﬁne the optimal duration of
treatment with antibiotics. In general, treatment duration
is 7--10 days for most antimicrobial agents and 14 days for
clarithromycin. Amoxicillin is considered the ﬁrst choice
antibiotic in primary health care centers, due to its effec-
tiveness and low cost. Macrolides have comparable efﬁcacy
to amoxicillin and are indicated for patients allergic to
-lactam antibiotics.22,25,26 In cases of suspected S. pneu-
moniae resistant to penicillin, severe cases and/or cases
associated with comorbidities, broad-spectrum antimicro-
bials are indicated.
Intranasal topical corticosteroids
Patients older than 12 years with post-viral RS, or uncompli-
cated ABRS patients with mild or moderate symptoms,24 and
without fever or intense facial pain,25 beneﬁt from topical
nasal corticosteroids as monotherapy. In addition to reliev-
ing the symptoms of rhinorrhea, nasal congestion, sinus
pain, and facial pain/pressure,24 topical corticosteroids min-
imize the indiscriminate use of antibiotics, reducing the risk
of bacterial resistance.25
Studies have suggested that topical nasal corticosteroids
associated with appropriate antibiotic therapy result in
more rapid relief of general and speciﬁc symptoms of
RS, especially congestion and facial pain,27--32 accelerating
patient recovery, even when there is no signiﬁcant improve-
ment in radiographic images.30,31,33 However, the optimal
dose and time of treatment are yet to be established.28--31
Although there are no studies that compare the effective-
ness of different types of nasal corticoids in ARS, many of
them, such as budesonide, mometasone furoate and ﬂu-
ticasone propionate have shown beneﬁts.33 Their use is
recommended for at least 14 days for symptom improve-
ment.
Oral corticosteroids
The use of oral corticosteroids is recommended for adult
patients with ABRS who have intense facial pain, as long as
they have no contraindications to their use.34,35 Oral cor-
ticosteroids should be used for three to ﬁve days, only in
the ﬁrst few days of the acute event, and always asso-
ciated with antibiotic therapy, shortening the duration of
facial pain34 and decreasing the consumption of conven-
tional analgesics.35 The evaluation after 10--14 days of
treatment shows that there are no signiﬁcant differences
in symptom resolution or treatment failure when compar-
ing isolated antibiotic therapy with oral corticosteroids.35
The few studies in the literature using oral corticosteroids
in the treatment of ABRS have shown favorable results with
methylprednisolone and prednisone.
Nasal lavage
Despite the frequent use of isotonic or hypertonic saline
solution in the nasal lavage of patients with rhinitis and RS,
little is known about its real beneﬁt in ARS.Randomized trials36 comparing nasal lavage with phys-
iological saline solution and hypertonic solution showed
greater patient intolerance to the hypertonic solution.
A meta-analysis of placebo-controlled, randomized and
•11
ouble-blind trials showed limited beneﬁt of nasal irrigation
ith nasal saline solution in adults, in general, not demon-
trating, any difference between patients and control
roups. Only one study showed a mean difference of
mprovement in the time of symptom resolution of 0.3 days,
ithout statistical signiﬁcance.37
In another meta-analysis in patients younger than 18
ears with ARS, there was no clear evidence that antihis-
amines, decongestants and nasal lavage were effective in
hildren with ARS.38
Despite little evidence of clinical beneﬁt, the use of nasal
aline lavage is generally recommended in patients with
RS. It results in improved ciliary function, reduces mucosal
dema and inﬂammatory mediators, thus helping to clean
he nasal cavity of the secretions of the infectious processes,
nd has no reported side effects.39
hronic rhinosinusitis
eﬁnition
RS is an inﬂammatory disease of the nasal mucosa that
ersists for at least 12 weeks. In speciﬁc cases, an isolated
inus involvement can be observed, as occurs in odontogenic
inusitis or in fungal ball. It can be divided phenotypically
nto two main entities: CRS with nasal polyposis (CRSwNP)
nd CRS without nasal polyposis (CRSsNP). Currently, there
s evidence to suggest that these two entities have distinct
hysiopathogenic mechanisms.
CRS is a common disease in the population and studies on
ts epidemiological data are important to evaluate its distri-
ution, analyze its risk factors and promote public health
olicies. However, such data are scarce in the literature.
dditionally, different deﬁnitions and the heterogeneity of
ethodologies used in the studies -- and, consequently, in
he results obtained -- make it difﬁcult to compare data.
linical diagnosis
everal clinical tests have been developed for the clinical
iagnosis of CRS, but in most patients it is based only on
he presence of sinonasal signs and symptoms, with a dura-
ion of greater than 12 weeks.40--42 Sinonasal endoscopy and
omputed tomography (CT) are complementary examina-
ions and help in disease classiﬁcation. In both the CRSwNP
nd CRSsNP forms, the main symptoms are:
Nasal obstruction41,42: Extremely subjective symptom. It
is one of the most frequent complaints in clinical practice,
affecting approximately 83.7% of the patients,43 being
even more important in patients with nasal polyposis. It is
caused by the congestion of sinusoidal vessels, resulting
in local edema, followed by tissue ﬁbrosis, and it sub-
sequently only resolves with the use of vasoconstrictors.
Although it is a subjective symptom, several articles in the
literature have validated nasal obstruction as an impor-
tant symptom of CRS, using acoustic rhinomanometry and
peak nasal inspiratory ﬂow.44
Rhinorrhea: It can be anterior or posterior, and can vary
from hyaline to mucopurulent secretion and is present in
63.6% of the patients with CRS. It may also be associated
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with cacosmia, cough and hoarseness. It is a difﬁcult
symptom to validate or quantify.43
Olfactory disorders: Hyposmia or even anosmia is fre-
quent, especially in CRSwNP, found in up to 46% of the
patients.42,43 It can be caused by an obstructive process
(polyps), mucosal edema and/or degeneration caused
by the chronic inﬂammatory process, with or without
the presence of nasal polyps,45 or due to local surgical
procedures.40 There are several tests with excellent
levels of evidence in the literature, which show olfactory
disorders in patients with CRS.15
Facial pain or pressure: Symptom with variable preva-
lence (18--80%).1 It is more often found in CRSwNP, in
patients with allergic rhinitis of difﬁcult control or during
exacerbation processes.1 Rhinogenic headache is an
diagnosis of exclusion, according to the International
Headache Society (IHS).1
Cough: It is a frequent symptom in childhood, often
unproductive, and may be the only manifestation present
in CRS. In addition to the usual symptoms, such as
phlegm, pharyngeal-laryngeal irritation, dysphonia,
halitosis, ear fullness, adynamia and sleep disorders
should be questioned.40--42 During the interview, it is
important, in addition to the classic symptoms already
described, to include questions about systemic diseases
and predisposing factors that may favor the development
of CRS. Personal habits such as smoking, cocaine use,
exposure to toxic inhalants, type of climate in the region
where the patient resides and environmental pollution
should be investigated.
Physical examination: Anterior rhinoscopy (with and
without vasoconstrictor): it is of limited usefulness,
except in cases of polyposis, when polyps can be visu-
alized by the simple inspection of the nasal vestibule.
However, it is important to describe signs such as hyper-
trophic inferior and middle turbinates, septal deviations
or mucosal degeneration. It is worth mentioning that
there are no pathognomonic signs of CRS.1,41
Oropharyngoscopy: The presence of retropalatal muco-
catarrhal secretion explains the symptom of postnasal
discharge, regardless of the color.1,41,42
omplementary examinations
asal endoscopy
asal endoscopy allows the systematic visualization of the
asal cavity (inferior, middle and upper turbinate), nasal
eptum, in addition to the nasopharynx and drainage path-
ays, and it can be performed with and without topical nasal
econgestants. The presence of polyps, mucosal degener-
tion, secretion, crusts, structural alterations, scars and
asal tumors may also be observed. It can be performed
t baseline or at regular intervals (e.g., 3, 6, 9, and 12
onths) to aid diagnosis, to supervise disease follow-up and
ostoperative periods, as well as to collect material for sup-
lementary tests.46,47
It is important to perform a systematic assessment
f the nasal cavities, such as: examination of the nasal
eptum, turbinates, visualization of the middle meatus, of
he sphenoethmoidal recess and of the nasopharynx. It is
lso necessary to verify the presence of crusts, ulcerations,
i
m
a
rAnselmo-Lima WT et al.
eptal perforation, signs of nasal bleeding as well as secret-
ons, and to exclude the possibility of associated polyposis
nd expansive lesions. It is very important to perform the
ndoscopic assessment of patients who are undergoing
r have previously had surgery. The evidence of mucosal
isease six months after surgery should be considered as
RS. Another factor to be taken into account in patients
ith previous surgery is the recirculation of mucus by
ot including the natural ostium of the maxillary sinus in
he antrostomy. Nasal endoscopy is an examination of the
tmost importance to aid diagnosis, to supervise disease
ollow-up and in the postoperative period, as well as to
ollect material for supplementary tests.
maging assessment
T is the method of choice for CRS; however, it is not the
rst step to attain diagnosis, except in cases of unilateral
igns and symptoms and suspected complication.
acterioscopy/sinus secretion culture
ndicated in cases refractory to treatment, and when the
aterial collected is not contaminated. It is performed by
uncture of the maxillary sinus through the canine fossa and
sing an endoscope, with the collection being performed in
he middle meatus.48
iopsy
t is important for the study and classiﬁcation of the inﬂam-
atory state of the CRS and nasal polyposis and it is
ndicated for the differential diagnosis of autoimmune, gran-
lomatous diseases and to rule out neoplasms (especially in
nilateral cases).
omments
he diagnostic investigation of CRS is based on the patient’s
atural history, signs and symptoms, endoscopic examina-
ion and CT. The latter is considered a main factor in the
nalysis of disease evolution and in the decision for sur-
ical intervention. The multiple causes of CRS can only
rovoke manifestations in the sinonasal region, but one
hould remember that the nasal cavity and paranasal sinuses
ay reﬂect the onset of systemic diseases. The identiﬁca-
ion of predisposing factors and diseases associated with RS
re of the utmost importance for adequate patient manage-
ent.
linical treatment
reatment with systemic and topical antimicrobials
he increasing perception of CRS as a multifactorial inﬂam-
atory process has been expressed clearly in the latest
onsensus, i.e., it is not a persistent bacterial infection.49
his fact has led to a mandatory theoretical reassessment of
ntimicrobial use for the treatment of this entity. However
n practice, unfortunately, it is not surprising that, this group
f drugs remains as a constant part of the drug arsenal used
n the everyday life of these patients, as well as persistently
dentiﬁed among the different proposals for the manage-
ent of this disease.50 This is possibly due to lack of both
lternatives and knowledge about the presence of bacte-
ia in the paranasal sinuses of these patients as free form
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and/or bioﬁlm. This main theoretical basis for the choice of
antibiotics also suffers from tools that allow the differentia-
tion of the actual role of the bacteria found in the paranasal
sinuses, as their identiﬁcation alone does not mean the pres-
ence of an infectious or inﬂammatory condition in response
to their presence.51 However, the identiﬁcation of bacteria
such as Staphylococcus and Pseudomonas at higher per-
centages in patients with recurrent events (postoperative)
continues to perpetuate the belief that they are part of the
CRS pathogenesis. For the purpose of illustration and ques-
tioning, in spite of the statistically signiﬁcant analysis, it
is noteworthy that in terms of percentage, the number of
positive cultures in this study was high both in the group
with poor outcome and in the group with favorable outcome
(87% vs. 73%), and for these speciﬁc bacteria the absolute
difference was of 14% (39% vs. 25%).52
Recent studies have investigated bacteria as necessary
and accountable elements, depending on their interaction
with the host, to maintain the balance of the inﬂammatory
response. The topical use of probiotics and bacteria in an
attempt to establish ﬂora and bioﬁlm inductors of sinonasal
homeostasis is an example.53
Over the past ﬁve years, there has been no new dramatic
evidence for the use of antimicrobials in CRS. Neverthe-
less, there is a recommendation for macrolide use in the
long term, for instance, in the absence of elevated serum
IgE.1,54--58 Meltzer et al.,59 in a review article, concluded
there is lack of publications capable of deﬁning a proven
effective proposal for the treatment of CRS, and empha-
sized that, for as long as the different presentations of the
disease are not well deﬁned, several treatments will follow
with limitations in result interpretation and extrapolation.
They also stressed that there are signs of increased inter-
est in the development of research; however, the simple
comparison of current records of randomized controlled tri-
als (RCTs) versus placebo, i.e., designs that are adequate
for the search of such responses at the National Institute
of Health (NIH -- ClinicalTrial.gov) does not allow the veriﬁ-
cation of this effort. (http://clinicaltrials.gov/ct2/results).
Thus, more speciﬁc inclusion and exclusion criteria, ran-
domization, prospective design, and study control arms are
required for the study of antibiotic treatment in CRS.
Comments
This is a warning regarding the frequent use of antimi-
crobials and the importance of being able to differentiate
them among the therapeutic options for the CRS. More-
over, there is not enough information in order for their use
to be completely discarded. It is necessary to ﬁnd ways
to identify the exact patient who could beneﬁt from the
use of antimicrobials in cases of unequivocal clinical ﬂare-
up and better identify the involved agents through culture
and sensitivity testing. The choice of extended antimicro-
bial use in CRSwNP cases, in which there is persistence
of severe symptoms that have not improved with multi-
ple treatments, including surgery, and even so, without
serum IgE elevation, still lacks proof of beneﬁt and its
possible biological effects must be carefully considered
when restricting its use. There is not enough evidence,
in quantitative and qualitative terms, to recommend the
s
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se of topical antibiotics for CRS with and without nasal
olyposis.
orticosteroids in chronic rhinosinusitis
herapy with topical and/or systemic corticosteroids (CS) is
valuable resource in the treatment of CRS. This effect has
een more decisively demonstrated in patients with poly-
osis. Although more evidence-based proof and studies are
ecessary, these agents are considered an adjuvant in the
ght against CRS in general, especially when used topically.
heir systemic administration is suggested for CRS cases with
ncontrolled symptoms, in which the aim is to decrease,
ven temporarily, the disease impact on the patient’s life.
n these situations, it is recommended to use the lowest
ffective dose for the shortest possible time to minimize
he potentially severe side effects.
reoperative use in patients with surgical indication
lthough there are differences of opinion, patients with
urulent CRSsNP can receive amoxicillin clavulanate 875mg
very 12 hours or cefuroxime 500mg every 12 hours pre-
peratively for 7--10 days, and maintain the treatment
ostoperatively for 7--21 days. In some cases, ﬂuoro-
uinolones and macrolides may be prescribed.
In patients with CRSwNP, the use of oral corticosteroids
or three to ﬁve days is suggested, maintaining the treat-
ent postoperatively, depending on the extent of disease.
xample: prednisolone 0.50mg/kg/day. Irrigation of the
asal mucosa with saline (isotonic) and hypertonic solutions,
ith and without preservatives, is a classic and safe measure
n the treatment of CRS and very useful in mobilizing sec-
etions and hydrating the mucosa pre- and postoperatively.
here is no evidence for their action as isolated treatment.49
urgical treatment: techniques
everal surgical techniques have been described for patients
ith CRSwNP and CRSsNP, refractory to medical treatment.
t is worth mentioning that there is no gold standard tech-
ique that can be applied to all cases. Due to the lack
f randomized controlled trials, several aspects of surgical
anagement remain controversial. The most important of
hem is the extent of surgical dissection. As a result, cur-
ent guidelines, primarily based on case-series studies and
xpert opinion, indicate that surgical management should
e individualized. The current trend in CRS with and with-
ut nasal polyposis (NP) is surgical dissection, extending as
ar as the extent of the disease.1
The most frequent surgical approach is the endonasal
ccess. However, some cases may require external or a com-
ined access. Examples are lateral maxillary or frontal sinus
esions, or even in cases with a lack of reliable anatomical
andmarks for an exclusively endonasal approach. Regard-
ess of the technique and instrumentation used, there is
learly a learning curve in endoscopic sinonasal surgery. It
s essential that the surgeon has deep knowledge of the
urgical anatomy and undergoes previous training through
peciﬁc courses to learn dissection of the nose and paranasal
inuses.
The surgical treatment of CRS has expanded greatly
ecause of the use of nasal endoscopy. The image accuracy
rovided by endoscopes (Optical 0 degree wide angle), as
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ell as their angulations (30, 45 and 70 degrees), allow the
isualization of all the details and recesses of the paranasal
avities. Moreover, the development of other speciﬁc equip-
ent and instruments for intranasal and sinus approach
e.g., dilation balloons, neuronavigator and microdebrider)
llows performing surgical procedures ranging from simple
ilation of the drainage ostia to complete marsupialization
f paranasal sinuses into the nasal cavity.60--62
ostoperative treatment -- topical
everal products have become available for postoperative
opical treatment. They can be used at high or low vol-
mes with high, low or negative pressure.63 The capacity
f the drug to reach the appropriate anatomical region
n the paranasal sinuses has been the subject of exten-
ive research over the past ﬁve years. The effective topical
herapy depends on several factors such as application tech-
ique, postoperative sinonasal anatomy and ﬂuid dynamics
volume, pressure, position). These combined factors seem
o have signiﬁcant impact on the effectiveness of topical
herapy in patients’ sinonasal mucosa.64--67
The mechanical removal of mucus, antigen, pollutants,
nﬂammatory products and bacteria/bioﬁlms is the aim of
opical treatment. This intervention very often depends on
igh-volume positive-pressure solutions to supply shearing
orces that can change the surface tension between liquid
nd air. However, the same approach may not be appropriate
or the use of pharmaceutical solutions that require prop-
rties promoting complete distribution within the paranasal
inus, long time of contact with the mucosa for local absorp-
ion and minimal wastage.63
It is considered very important to continue medical treat-
ent postoperatively in almost all forms of CRS. Currently,
t is recommended to use nasal saline wash and topical
asal corticosteroids after sinonasal endoscopic surgery for
RS.63,68 The drug use directly at the disease site has
he advantage of allowing high local doses and minimiz-
ng side effects.64 The distribution of the topical solution
o the non-operated sinuses seems to be limited. Thus,
inonasal endoscopic surgery is essential to allow effective
opical distribution to the paranasal sinuses.1 Postoperative
istribution is superior with high-volume positive-pressure
evices.65--67 Low-volume sprays and drops have poor distri-
ution and should be considered as treatment only for the
asal cavity, especially before sinonasal endoscopic surgery.
here are limited data on the exact amount necessary
o allow complete distribution. Nasal lavage with isotonic
aline solution may be used in the immediate CRS postopera-
ive period, as well as topical nasal corticosteroids, which
ay be started two to three weeks after surgery, or after
rust disappearance. There are no relevant data in the liter-
ture to support the postoperative use of other nasal topical
gents in CRS.
ostoperative treatment -- systemic
orticosteroids (CS). After the surgical treatment of CRS,
ystemic corticosteroids (CS) can be used in basically two
ays: in short doses, of between seven and 14 days, with
ose maintenance for the entire treatment, or for longer
eriods, using tapering doses.69,70 The primary role of the
S in this type of disease is to reduce mucosal inﬂammation,
p
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hus providing better surgical outcomes. However, use of this
edication is still avoided by many surgeons due to their
otential side effects.
ntibiotics. The purpose of antibiotic use postoperatively
s to prevent infection of the secretions retained in the
aranasal sinuses immediately after surgery. If there is puru-
ent secretion during the surgical procedure, antibiotics
hould be prescribed, based on the culture and sensitivity
esting. Otherwise, antibiotics effective against the most
ommon pathogens should be employed.70
Despite the scarcity of literature data on antibiotic effec-
iveness in the postoperative period of endoscopic sinonasal
urgery, it is believed that they can improve symptoms and
ndoscopic appearance, if used for a longer period (at least
4 days), but there are no conclusive data about the duration
f these beneﬁts. In general, penicillin derivatives, particu-
arly amoxicillin + clavulanic acid and cefuroxime axetil are
he agents most often used.
pecial aspects of rhinosinusitis in children
iagnosis
he clinical diagnosis of ARS in children is not easy to attain.
any symptoms are common to other childhood diseases
uch as colds, ﬂu and allergic rhinitis. Additionally, there
re limitations and difﬁculties related to the clinical exam-
nation in the pediatric population.
ost common signs and symptoms
tudies in children with ARS show that the clinical picture
ften includes fever (50--60%), rhinorrhea (71--80%), cough
50--80%) and pain (29--33%),71 plus retronasal secretion and
asal obstruction.72 In children up to preschool age, the pain
ymptom has a low prevalence, being replaced by coughing.
s for schoolchildren and adolescents, pain as a symptom
ecomes more common.
Although there are not many studies, most medical pro-
essionals and guidelines recommend that the diagnosis of
acterial ARS be clinical, based on the time of evolution
URTI symptoms for more than 10 days), the abrupt onset of
igh-intensity symptoms (as early as in the ﬁrst 4 days), or
ymptom worsening after an initial period of improvement
uring a URTI, known as double worsening. The follow-
ng may be part of the signs and symptoms: high fever,
rofuse nasal purulent discharge, periorbital edema and
acial pain.1,72--76
linical examination
n addition to the abovementioned signs and symptoms,
asal endoscopy helps in diagnosing and differentiating
etween viral and bacterial disease, enhancing the visu-
lization of nasal secretion and the nasopharynx. When
ositive for ABRS (purulent secretion draining from the mid-
le meatus), the diagnosis is conﬁrmed. However, purulent
ecretions are not always easy to visualize in children. More-
ver, despite the high speciﬁcity, it has a low degree of
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sensitivity, as a negative test does not exclude the diagnosis
of ABRS.
Imaging study
There is a near consensus in all the most recent guidelines
that the diagnosis of ARS should not be based on radiological
studies, particularly on plain radiographs.1,73,76
Viral processes in children often involve the sinuses. Chil-
dren exhibiting symptoms of URTI with at least six days
duration of the clinical picture usually show signs of abnor-
mality in all sinuses: maxillary and ethmoid, sphenoid and
frontal, in order of frequency. The opaciﬁcation is nonspe-
ciﬁc and may occur in viral, bacterial and allergic processes,
as well as in tumors, or even due to sinus nonformation in
particular.
CT studies in children with a clinical picture suggestive
of ARS showed that even the most important ﬁndings show
signiﬁcant regression of alterations after two weeks.77 Indi-
cations for CT in acute sinus conditions should therefore be
reserved for patients who do not improve and whose symp-
toms persist after appropriate therapy, as well as those with
suspected complications.74
Drug treatment of ARS in children
Most are self-limited, resolving spontaneously.1
Antibiotic therapy
Results of meta-analysis suggest that the rate of improve-
ment and resolution in ARS between 7 and 15 days is
slightly higher when antibiotic therapy is used.78 For this
reason, it is believed that antibiotics should be reserved for
more severe cases or when there are concomitant diseases
present that could be exacerbated by ARS, such as asthma
and chronic bronchitis.1,73,75 However, there is no univer-
sal consensus regarding antibiotic use in ARS. In general,
amoxicillin (40mg/kg/day or 80mg/kg/day) is still indicated
as a reasonable initial treatment in most studies. Amoxi-
cillin/clavulanate and cephalosporins are considered good
options against beta lactamase producers1 and are indicated
in cases of ﬁrst treatment failure.
Similar to the recommendations for acute otitis media,
in ARS there is also the option of a single dose of ceftria-
xone 50mg/kg IV (intravenous) or IM (intramuscular) for
children who are vomiting and thus unable to tolerate oral
medication.11--13 If there is clinical improvement in 24 h,
treatment is completed with oral antibiotics.75
For penicillin-allergic patients, there is some contro-
versy among the latest international guidelines. Some
consider trimethoprim/sulfamethoxazole, macrolides and
clindamycin good ﬁrst choices1 in these situations. Others do
not recommend the use of trimethoprim/sulfamethoxazole
and macrolides due to the increasing resistance of Pneumo-
cocci and H. inﬂuenzae to these drugs, and suggest a
quinolone, such as levoﬂoxacin, as an alternative, especially
in older children, even in view of toxicity, high cost and
emerging resistance.79,80 There are no reviews on the opti-
mal treatment duration. Recommendations based on clinical
observations have shown varied results, from 10 to 28 days
i
t
T
r15
f treatment. One suggestion has been to maintain therapy
or seven days after symptom resolution.81
ntranasal corticosteroids
ntranasal CS for three weeks associated with the antibiotic
eems to have advantages when compared to treatment of
RS in children and adolescents with antibiotic alone, espe-
ially in relation to cough and nasal discharge.28,35,38 There
s also some evidence, based on a single double-blind, ran-
omized trial, that in patients older than 12 years, a double
ose of intranasal CS as a single drug may be more effective
n controlling the ARS than the antibiotic therapy alone.28
ecurrent ARS (RARS)
ost authors agree that RARS is deﬁned by acute episodes
asting less than 30 days, with intervals of at least 10 days
ith a completely asymptomatic patient. According to some
uthors, the patient should have at least four episodes a year
o meet the criteria for recurrence.75
As in chronic conditions, one should seek to rule out
ome causes of systemic origin. The investigation should
nclude allergic processes, by performing speciﬁc tests;
mmunoglobulin deﬁciencies, with quantitative research,
articularly IgA and IgG; cystic ﬁbrosis; gastroesophageal
eﬂux, and ciliary diseases.82 Pharyngeal tonsil hypertro-
hy, even mild, should also be considered, since it can act
s a reservoir for pathogens. Anatomical factors, although
sually not relevant in children, should also be ruled out
concha bullosa, septal deviation, etc.). In these cases, CT,
asal endoscopy and/or magnetic resonance imaging (MRI)
ay aid in the diagnosis of the obstructive process and of
alformation.
The bacteriology is the same as for ARS and, there-
ore, the treatment of the acute phase should follow the
ame principles.83 Unfortunately, it is necessary to recog-
ize that the frequent use of antibiotics at short intervals
an contribute to bacterial resistance. Prophylaxis with
ntimicrobials should be reserved for exceptional cases,
sually those with conﬁrmed underlying diseases, particu-
arly immunodeﬁciencies.
The following overall prophylactic measures are recom-
ended: annual vaccination for inﬂuenza and pneumococcal
accine. In cases where allergic rhinitis or gastroesophageal
eﬂux are associated, the frequency of acute events
ecreases when the associated disease is treated. Several
tudies have demonstrated that immunostimulatory medi-
ations such as bacterial lysates help control recurrent viral
nd bacterial RTIs, and may be an adjunct therapy in the
ontrol of RARS.84
articularities of chronic rhinosinusitis in
hildren
RS in children is not as frequently studied as it is in adults
nd its prevalence has not yet been fully established. It
s believed that several factors contribute to the disease,
ncluding inﬂammatory and bacteriological factors, and that
he pharyngeal tonsil is an important factor in this age group.
reatment is primarily with drugs, and surgical therapy is
eserved for the minority of patients.
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linical and diagnostic picture
he clinical diagnosis of chronic rhinosinusitis in children is
till considered a challenge, as it often overlaps those of
ther common childhood diseases, such as viral infections
f the upper respiratory tract, hypertrophy, with or without
nfection of the pharyngeal tonsils and adenoids and allergic
hinitis. The most important signs and symptoms include
asal blockage/obstruction/congestion, rhinorrhea (ante-
ior/posterior),± facial pain/pressure, cough± and/or
ndoscopic signs of disease. CT can show relevant changes
n the paranasal sinuses.1
maging studies
tudies that have assessed the incidence of abnormalities
n the paranasal sinuses on CT, obtained for clinical reasons
nrelated to the CRS in children have shown a percentage of
inus radiographic abnormalities ranging from 18%2,3 to 45%,
ercentages that are similar to those found in children with
RS symptoms. This demonstrates that the signiﬁcance of
n imaging study is relative and must always be considered
ogether with the clinical picture.
acteriology
here are few studies on the bacteriology of CRS in children.
icroorganisms that have already been found in aspirates
r intraoperatively include: S. alpha hemolytic and Staphy-
ococcus aureus, S. pneumoniae, H. inﬂuenzae and M.
atarrhalis, as well as anaerobic organisms such as bac-
eroides and Brook I fusobacterium.85--87
reatment
rug treatment
urrent studies demonstrate that the treatment of CRS in
hildren with antibiotics for a short period of time is not
ustiﬁable.1 On the other hand, both nasal CS and saline
olution have shown beneﬁts, and are considered ﬁrst-line
reatments for this disease, with or without the presence of
olyps.88,89
urgical treatment
he surgical approach should always be reserved for special
ases, i.e., children who have not responded to appropriate
edical treatment. Studies have shown signiﬁcant improve-
ent in the clinical picture and in quality of life, without
egative repercussions in relation to facial osteoskeletal
equelae.90 Unfortunately, the majority of studies sup-
orting this recommendation do not have a prospective,
andomized design. In general, the surgical approach, when
ndicated, may consist initially of an adenoidectomy,90 with
axillary sinus lavage.91 Surgery can be performed with or
ithout balloon dilation,92,93 followed by paranasal sinus
ndoscopic surgery in case of symptom recurrence.94 In
ases of children with cystic ﬁbrosis, NP, antrochoanal polyps
r allergic fungal RS, endoscopic surgery is the ﬁrst option.
erhaps future studies comparing the different methods
f treatment with standardized symptom questionnaire,
1Anselmo-Lima WT et al.
re- and postoperatively, can guide the best therapeutic
pproach in pediatric patients with CRS.
onﬂicts of interest
he authors declare no conﬂicts of interest.
eferences
1. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody
F, et al. European position paper on rhinosinusitis 4and nasal
polyps 2012. Rhinol Suppl. 2012;23:1--298.
2. Kosugi EM, Chen VG, Fonseca VMGD, Cursino MMP, Mendes
Neto JA, Gregorio LC. Translation, cross-cultural adaptation and
validation of SinoNasal Outcome Test (SNOT): 22 to Brazilian
Portuguese. Br J Ophthalmol. 2011;77:663--9.
3. Hopkins C. Patient reported outcome measures in rhinology.
Rhinology. 2009;47:10--7.
4. Morley AD, Sharp H. A review of sinonasal outcome scoring sys-
tems -- which is best? Clin Otolaryngol. 2006;31:103--9.
5. Williams JW Jr, Simel DL, Roberts L, Samsa GP. Clinical evalu-
ation for sinusitis. Making the diagnosis by history and physical
examination. Ann Intern Med. 1992;117:705--10.
6. Damm M, Quante G, Jungehuelsing M, Stennert E. Impact of
functional endoscopic sinus surgery on symptoms and quality of
life in chronic rhinosinusitis. Laryngoscope. 2002;112:310--5.
7. Spector SL, Bernstein IL, Li JT, Berger WE, Kaliner MA, Schuller
DE, et al. Parameters for the diagnosis and management of
sinusitis. J Allergy Clin Immunol. 1998;102:S107--44.
8. Rosenfeld RM, Andes D, Bhattacharyya N, Cheung D, Eisenberg
S, Ganiats TG, et al. Clinical practice guideline: adult sinusitis.
Otolaryngol Head Neck Surg. 2007;137:S1--31.
9. Hansen JG. Management of acute rhinosinusitis in Danish gen-
eral practice: a survey. Clin Epidemiol. 2011;3:213--6.
0. Desrosiers M, Evans GA, Keith PK, Wright ED, Kaplan A, Bouchard
J, et al. Canadian clinical practice guidelines for acute and
chronic rhinosinusitis. Allergy Asthma Clin Immunol. 2011;7:2.
1. Lacroix JS, Ricchetti A, Lew D, Delhumeau C, Morabia A, Stalder
H, et al. Symptoms and clinical and radiological signs predicting
the presence of pathogenic bacteria in acute rhinosinusitis. Arch
Otolaryngol. 2002;122:192--6.
2. Lindbaek M, Hjortdahl P, Johnsen UL. Use of symptoms, signs,
and blood tests to diagnose acute sinus infections in pri-
mary care: comparison with computed tomography. Fam Med.
1996;28:183--8.
3. Lindbaek M, Hjortdahl. The clinical diagnosis of acute puru-
lent sinusitis in general practice-a review. Br J Gen Pract.
2002;52:491--5.
4. Cain WS. Testing olfaction in a clinical setting. Ear Nose Throat
J. 1989;68:22--8.
5. Cardesin A, Alobid I, Benitez P, Sierra E, de Haro J, Bernal-
Sprekelsen M, et al. Barcelona Smell Test - 24 (BAST-24):
validation and smell characteristics in the healthy Spanish pop-
ulation. Rhinology. 2006;44:83--9.
6. Fornazieri MA, Doty RL, Santos CA, Pinna FR, Bezerra TFP,
Voegels RL. A new cultural adaptation of the University of Penn-
sylvania Smell Identiﬁcation Test. Clinics. 2013;68:65--8.
7. Berg O, Carenfelt C. Analysis of symptoms and clinical
signs in the maxillary sinus empyema. Arch Otolaryngol.
1988;105:343--9.
8. Hansen JG, Hojbjerg T, Rosborg J. Symptoms and signs in
culture-proven acute maxillary sinusitis in a general practice
population. APMIS. 2009;117:724--9.
9. Gwaltney JM Jr, Hendley JO, Simon G, Jordan WS Jr. Rhinovirus
infections in an industrial population. II. Characteristics of ill-
ness and antibody response. JAMA. 1967;202:494--500.
33
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
5
5
5
5Rhinosinusitis: evidence and experience
20. Young J, De Sutter A, Merenstein D, van Essen GA, Kaiser L,
Varonen H, et al. Antibiotics for adults with clinically diagnosed
acute rhinosinusitis: a meta-analysis of individual patient data.
Lancet. 2008;371:908--14.
21. Merenstein D, Whittaker C, Chadwell T, Wegner B, D’Amico
F. Are antibiotics beneﬁcial for patients with sinusitis com-
plaints? A randomized double-blind clinical trial. J Fam Pract.
2005;54:144--51.
22. Benninger MS, Sedory Holzer SE, Lau J. Diagnosis and treatment
of uncomplicated acute bacterial rhinosinusitis: summary of
the Agency for Health Care Policy and Research evidence-based
report. Otolaryngol Head Neck Surg. 2000;122:1--7.
23. Meltzer EO, Bachert C, Staudinger H. Treating acute rhinosi-
nusitis: comparing efﬁcacy and safety of mometasone furoate
nasal spray, amoxicilin, and placebo. J Allergy Clin Immunol.
2005;116:1289--95.
24. de Ferranti SD, Ioannidis JP, Lau J, Anninger WV, Barz M. Are
amoxicillin and folate inhibitors as effective as other antibiotics
for acute sinusitis? A meta-analysis. BMJ. 1998;317:632--7.
25. Ip S, Fu L, Balk E, Chew P, Devine D, Lau J. Update on
acute bacterial rhinosinusitis. Evid Rep Technol Assess (Summ).
2005;124:1--3.
26. Tan T, Little P, Stokes T, Guideline Development Group. Antibi-
otic prescribing for self limiting respiratory tract infections
in primary care: summary of NICE guidance. BMJ. 2008;337:
a437.
27. Small CB, Bachert C, Lund VL, Moscatello A, Nayak AS, Berger
WE. Judicious antibiotic use and intranasal corticosteroids in
acute rhinosinusitis. Am J Med. 2007;120:289--94.
28. Barlan IB, Erkan E, Bakir M, Berrak S, Basaran M. Intranasal
budesonide spray as an adjunt to oral antibiotic therapy
for acute sinusitis in children. Ann Allergy Asthma Immunol.
1997;78:598--601.
29. Yilmaz G, Varan B, Yilmaz T, Gürakan B. Intranasal budes-
onide spray as an adjunct to oralantibiotic therapy for acute
sinusitis in children. Eur Arch Otorhinolaryngol. 2000;257:
256--9.
30. Meltzer EO, Charous L, Busse WW, Zinreich J, Lorber RR, Danzig
MR. Added relief in the treatment of acute recurrent sinusitis
with adjunctive mometasone furoate nasal spray. The Nasonex
Sinusitis Group. J Allergy Clin Immunol. 2000;106:630--7.
31. Nayak AS, Settipane GA, Pedinoff A, Charous L, Meltzer EO,
Busse WW, et al. Effective dose range of mometasone furoate
nasal spray in the treatment of acute rhinosinusitis. Ann Allergy
Asthma Immunol. 2002;89:271--8.
32. Dolor RJ, Witsell DL, Hellkamp AS, Williams JW Jr, Califf
RM, Simel DL, et al. Comparison of cefuroxime with or
without intranasal ﬂuticasone for the treatment of rhinosi-
nusitis. The CAFFS Trial: a randomized controlled trial. JAMA.
2001;286:3097--105.
33. Meltzer EO, Orgel A, Backhaus JW, Busse WW, Druce HM,
Metzger J, et al. Intranasal ﬂunisolide spray as an adjunt to
oral antibiotics therapy for sinusitis. J Allergy Clin Immunol.
1993;92:812--23.
34. Gehanno P, Beauvillain C, Bobin S, Chobaut JC, Desaulty A,
Dubreuil C, et al. Short therapy with amoxicillin-clavulanate
and corticosteroids in acute sinusitis: results of a multicentre
study in adults. Scand J Infect Dis. 2000;32:679--84.
35. Klossek JM, Desmonts-Gohler C, Des-landes B, Coriat F, Bor-
dure P, Dubreuil C, et al. Treatment of functional signs of
acute maxillary rhinosinusitis in adults. Efﬁcacy and tolerance
of administration of oral prednisone for 3 days. Presse Med.
2004;33:303--9.
36. Adam P, Stiffman M, Blake RL Jr. A clinical trial of hypertonic
saline nasal spray in subjects with the common cold or rhinosi-
nusitis. Arch Fam Med. 1998;7:39--43.
37. Kassel JC, King D, Spurling GK. Saline nasal irrigation for acute
upper respiratory tract infections. CDS Rev. 2010. CD006821.
517
8. Shaikh N, Wald ER, Pi M. Decongestants, antihistamines and
nasal irrigation for acute sinusitis in children. CDS Rev. 2012;9.
CD007909.
9. Tomooka LT, Murphy C, Davidson TM. Clinical study
and literature review of nasal irrigation. Laryngoscope.
2000;110:1189--93.
0. Fokkens W, Lund V, Mullol J, European Position Paper on
Rhinosinusitis and Nasal Polyps Group. European position
paper on rhinosinusitis and nasal polyps 2007. Rhinol Suppl.
2007;20:1--136.
1. Marple BF, Stankiewicz JA, Baroody FM, Chow JM, Conley DB,
Corey JP, et al. Diagnosis and management of chronic rhinosi-
nusitis in adults. Postgrad Med. 2009;121:121--39.
2. Bhattacharyya N. Clinical and symptom criteria for the
accurate diagnosis of chronic rhinosinusitis. Laryngoscope.
2006;116:1--22.
3. Hastan D, Fokkens WJ, Bachert C, Newson RB, Bislimovska
J, Bockelbrink A, et al. Chronic rhinosinusitis in Europe -- an
underestimated disease. A GA(2)LEN study. Allergy. 2011;66:
1216--23.
4. Numminen J, Ahtinen M, Huhtala H, Rautiainen M. Comparison
of rhinometric measurements methods in intranasal pathology.
Rhinology. 2003;41:65--8.
5. Hox V, Bobic S, Callebaux I, Jorissen M, Hellings PW. Nasal
obstruction and smell impairment in nasal polyp disease: corre-
lation between objective and subjective parameters. Rhinology.
2010;48:426--32.
6. Hughes RG, Jones NS. The role of nasal endoscopy in outpatient
management. Clin Otolaryngol Allied Sci. 1998;23:224--6.
7. Bhattacharyya N, Lee LN. Evaluating the diagnosis of chronic
rhinosinusitis based on clinical guidelines and endoscopy.
Otolaryngol Head Neck Surg. 2010;143:147--51.
8. Araujo E, Dall C, Cantarelli V, Pereira A, Mariante AR. Micro-
biologia do meato médio na rinossinusite crônica. Rev Bras
Otorrinolaringol. 2007;73:549--55.
9. Diretrizes Brasileiras de Rinossinusites. Rev Bras Otorrino-
laringol. 2008;74:6--59.
0. Dubin MG, Liu C, Lin SY, Senior BA. American Rhinologic Soci-
ety member survey on ‘‘maximal medical therapy’’ for chronic
rhinosinusitis. Am J Rhinol. 2007;21:483--8.
1. Pandak N, Pajic´-Penavic´ I, Sekelj A, Tomic´-Paradzˇik M, Cabraja I,
Miklausˇic´ B. Bacterial colonization or infection in chronic sinus-
itis. Wien Klin Wochenschr. 2011;123:710--3.
2. Cleland EJ, Bassiouni A, Wormald PJ. The bacteriology of
chronic rhinossinusitis and the pre-eminence of Staphylococ-
cus aureus in revision patients. Int Forum Allergy Rhinol.
2013;3:642--6.
3. Cleland EJ, Drilling A, Bassiouni A, James C, Veugrede S,
Wormald PJ. Probiotic manipulation of the chronic rhinossinusi-
tis microbiome. Int Forum Allergy Rhinol. 2014;4:309--14.
4. Piromchai P, Kasemsiri P, Laohasiriwong S, Thanaviratananich
S. Chronic rhinosinusitis and emerging treatment options. Int J
Gen Med. 2013;6:453--64.
5. Adelson RT, Adappa ND. What is the proper role of oral antibi-
otics in the treatment of chronic sinusitis? Curr Opin Otolaryngol
Head Neck Surg. 2013;21:61--8.
6. Soler ZM, Oyer SL, Kern RC, Senior BA, Kountakis SE, Marple BF,
et al. Antimicrobials and chronic rhinosinusitis with or without
polyposis in adults: an evidenced-based review with recommen-
dations. Int Forum Allergy Rhinol. 2013;3:31--47.
7. Mandal R, Patel N, Ferguson BJ. Role of antibiotics in sinusitis.
Curr Opin Infect Dis. 2012;25:183--92.
8. Piromchai P, Thanaviratananich S, Laopaiboon M. Systemic
antibiotics for chronic rhinosinusitis without nasal polyps in
adults. CDS Rev. 2011. CD008233.9. Meltzer EO, Hamilos DL. Rhinosinusitis diagnosis and man-
agement for the clinician: a synopsis of recent consensus
guidelines. Mayo Clin Proc. 2011;86:427--43.
16
6
6
6
6
6
6
6
6
6
7
7
7
7
7
7
7
7
7
7
8
8
8
8
8
8
8
8
8
8
9
9
9
98
0. Dalgorf DM, Sacks R, Wormald PJ, Naidoo Y, Panizza B, Uren B,
et al. Image-guided surgery inﬂuences perioperative from ESS:
a systematic review and meta-analysis. Otolaryngol Head Neck
Surg. 2013;149:17--29.
1. Ahmed J, Pal S, Hopkins C, Jayaraj S. Functional endoscopic
balloon dilation of sinus ostia for chronic rhinosinusitis. CDS Rev.
2011. CD008515.
2. Naidoo Y, Bassiouni A, Keen M, Wormald PJ. Long-term outcomes
for the endoscopic modiﬁed Lothrop/Draf III procedure: a 10-
year review. Laryngoscope. 2014;124:43--9.
3. Harvey RJ, Psaltis A, Schlosser RJ, Witterick IJ. Current con-
cepts in topical therapy for chronic sinonasal disease. J
Otolaryngol Head Neck Surg. 2010;39:217--31.
4. Moller W, Schuschnig U, Celik G, Munzings W, Bartenstein P,
Haussinger P, et al. Topical Drug delivery in chronic rhinosinusitis
patients before and after sinus surgery using pulsating aerosols.
PLoS ONE. 2013;6:e74991.
5. Harvey RJ, Goddard JC, Wise SK, Schlosser RJ. Effects of endo-
scopic sinus surgery and delivery device on cadavers in us
irrigation. Otolaryngol Head Neck Surg. 2008;139:137--42.
6. Snidvongs K, Chaowanapanja P, Aeumjaturapat S, Chusakul S,
Praweswararat P. Does nasal irrigationenter paranasal sinuses
in chronicrhinosinusitis? Am J Rhinol. 2008;22:483--6.
7. Grobler A, Weitzel EK, Buele A, Jardeleza C, Cheong YC, Field
J, et al. Pre- and postoperative sinus penetration of nasal
irrigation. Laryngoscope. 2008;118:2078--81.
8. Wei CC, Adappa ND, Cohen NA. Use of topical nasal thera-
pies in the management of chronic rhinosinusitis. Laryngoscope.
2013;123:2347--59.
9. Rudmik L, Smith TL. Evidence-based practice: postoperative
care in endoscopic sinus surgery. Otolaryngol Clin North Am.
2012;45:1019--32.
0. Orlandi RR, Hwang PH. Perioperative care for advanced rhinol-
ogy procedures. Otolaryngol Clin North Am. 2006;39:463--73,
viii.
1. Wang DY, Wardani RS, Singh K, Thanaviratananich S, Vicente G,
Xu G, et al. A survey on the management of acute rhinosinusitis
among Asian physicians. Rhinology. 2011;49:264--71.
2. Lin SW, Wang YH, Lee MY, Ku MS, Sun HL, Lu KH, et al.
Clinical spectrum of acute rhinosinusitis among atopic and
nonatopic children in Taiwan. Int J Pediatr Otorhinolaryngol.
2012;76:70--5.
3. Chow AW, Benninger MS, Brook I, Brozek JL, Goldstein EJ,
Hicks LA, et al. IDSA clinical practice guideline for acute bac-
terial rhinosinusitis in children and adults. Clin Infect Dis.
2012;54:e72--112.
4. Wald ER. Beginning antibiotics for acute rhinosinusitis and
choosing the right treatment. Clin Rev Allergy Immunol.
2006;30:143--52.
5. Wald ER, Applegate KE, Bordley C, Darrow DH, Glode MP, Marcy
SM, et al. Clinical practice guideline for the diagnosis and man-
agement of acute bacterial sinusitis in children aged 1 to 18
years. Pediatrics. 2013;132:e262--80.
6. Kristo A, Uhari M, Luotonen J, Koivunen P, Ilkko E, Tapiainen
T, et al. Paranasal sinus ﬁndings in children during respiratory
infection evaluated with magnetic resonance imaging. Pedi-
atrics. 2003;111:e586--9.
7. Marseglia GL, Pagella F, Klersy C, Barberi S, Licari A, Ciprandi
G. The 10-day mark is a good way to diagnose not only acute
9Anselmo-Lima WT et al.
rhinosinusitis but also adenoiditis, as conﬁrmed by endoscopy.
Int J Pediatr Otorhinolaryngol. 2007;71:581--3.
8. Falagas ME, Giannopoulou KP, Vardakas KZ, Dimopoulos G, Kara-
georgopoulos DE. Comparison of antibiotics with placebo for
treatment of acute sinusitis: a meta-analysis of randomised
controlled trials. Lancet Infect Dis. 2008;8:543--52.
9. Critchley IA, Jacobs MR, Brown SD, Traczewski MM, Tillotson GS,
Janjic N. Prevalence of serotype 19A Streptococcus pneumoniae
among isolates from U.S. children in 2005--2006 and activity of
faropenem. Antimicrob Agents Chemother. 2008;52:2639--43.
0. Jacobs MR, Good CE, Windau AR, Bajaksouzian S, Biek D, Critch-
ley IA, et al. Activity of ceftaroline against recent emerging
serotypes of Streptococcus pneumoniae in the United States.
Antimicrob Agents Chemother. 2010;54:2716--9.
1. American Academy of Pediatrics, Sub-committee on Manage-
ment of Sinusitis and Committee on Quality Improvement.
Clinical practice guideline: management of sinusitis. Pediatrics.
2001;108:798--808.
2. Shapiro GG, Virant FS, Furukawa CT, Pierson WE, Bierman CW.
Immunologic defects in patients with refractory sinusitis. Pedi-
atrics. 1991;87:311--6.
3. Brook I, Gober AE. Antimicrobial resistance in the nasopha-
ryngeal ﬂora of children with acute maxillary sinusitis and
maxillary sinusitis recurring after amoxicillin therapy. J Antimi-
crob Chemother. 2004;53:399--402.
4. Schaad UB. OM-85 BV, an immunostimulant in pediatric recur-
rent respiratory tract infections: a systematic review. World J
Pediatr. 2010;6:5--12.
5. Brook I. Bacteriology of acute and chronic ethmoid sinusitis. J
Clin Microbiol. 2005;43:3479--80.
6. Muntz HR, Lusk RP. Bacteriology of the ethmoid bullae in chil-
dren with chronic sinusitis. Arch Otolaryngol Head Neck Surg.
1991;117:179--81.
7. Hsin CH, Su MC, Tsao CH, Chuang CY, Liu CM. Bacteriology and
antimicrobial susceptibility of pediatric chronic rhinosinusitis:
a 6-year result of maxillary sinus punctures. Am J Ophthalmol.
2010;31:145--9.
8. Harvey R, Hannan SA, Badia L, Scadding G. Nasal saline irri-
gations for the symptoms of chronic rhinosinusitis. Cochrane
Database Syst Rev. 2007:CD006394.
9. Ozturk F, Bakirtas A, Ileri F, Turktas I. Efﬁcacy and tolerabil-
ity of systemic methylprednisolone in children and adolescents
with chronic rhinosinusitis: a double-blind, placebo-controlled
randomized trial. J Allergy Clin Immunol. 2011;128:348--52.
0. Brietzke SE, Brigger MT. Adenoidectomy outcomes in pediatric
rhinosinusitis: a meta-analysis. Int J Pediatr Otorhinolaryngol.
2008;72:1541--5.
1. Criddle MW, Stinson A, Savliwala M, Coticchia J. Pediatric
chronic rhinosinusitis: a retrospective review. Am J Ophthalmol.
2008;29:372--8.
2. Ramadan HH, Cost JL. Outcome of adenoidectomy versus ade-
noidectomy with maxillary sinus wash for chronic rhinosinusitis
in children. Laryngoscope. 2008;118:871--3.
3. Ramadan HH, Terrell AM. Balloon catheter sinuplasty and ade-
noidectomy in children with chronic rhinosinusitis. Ann Otol
Rhinol Laryngol. 2010;119:578--82.
4. Hebert RL 2nd, Bent JP 3rd. Meta-analysis of outcomes of
pediatric functional endoscopic sinus surgery. Laryngoscope.
1998;108:796--9.
